2015, ISBN 1783463503, 248 p., 16 unnumbered p.s of plates
Book
2016, ISBN 1785700545, iv, 193 pages
Book
Journal of Infection, ISSN 0163-4453, 2014, Volume 69, Issue 3, pp. 216 - 225
Summary Background An intervention for Gram-negative bloodstream infections that integrated mass spectrometry technology for rapid diagnosis with antimicrobial...
Infectious Disease | Bloodstream infections | Multidrug resistant | Antimicrobial stewardship | MALDI-TOF | Rapid diagnostics | MORTALITY | ACQUIRED INFECTIONS | INFECTIOUS DISEASES | METAANALYSIS | IDENTIFICATION | DISEASES SOCIETY | IMPACT | THERAPY | HEALTH-CARE | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Humans | Middle Aged | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Gram-Negative Bacterial Infections - microbiology | Time Factors | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Time-to-Treatment | Bacteremia - drug therapy | Klebsiella - enzymology | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas Infections - diagnosis | Survival Rate | Pseudomonas Infections - microbiology | Klebsiella Infections - diagnosis | Gram-Negative Bacterial Infections - diagnosis | Hospital Costs | Escherichia coli Infections - mortality | Pseudomonas aeruginosa - isolation & purification | beta-Lactam Resistance | Acinetobacter Infections - mortality | Klebsiella - isolation & purification | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Acinetobacter baumannii - isolation & purification | Adult | Female | beta-Lactamases - metabolism | Acinetobacter Infections - microbiology | Length of Stay | Escherichia coli Infections - diagnosis | Intensive Care Units | Klebsiella Infections - drug therapy | Acinetobacter Infections - diagnosis | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Treatment Outcome | Bacteremia - diagnosis | Klebsiella Infections - microbiology | Escherichia coli - isolation & purification | Klebsiella Infections - mortality | Aged | Gram-Negative Bacterial Infections - mortality | Drug resistance in microorganisms | Care and treatment | Mass spectrometry | Patient outcomes
Infectious Disease | Bloodstream infections | Multidrug resistant | Antimicrobial stewardship | MALDI-TOF | Rapid diagnostics | MORTALITY | ACQUIRED INFECTIONS | INFECTIOUS DISEASES | METAANALYSIS | IDENTIFICATION | DISEASES SOCIETY | IMPACT | THERAPY | HEALTH-CARE | BLOOD-STREAM INFECTIONS | ENTEROBACTERIACEAE | Humans | Middle Aged | Bacteremia - mortality | Male | Pseudomonas Infections - mortality | Gram-Negative Bacterial Infections - microbiology | Time Factors | Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | Escherichia coli Infections - drug therapy | Escherichia coli - enzymology | Time-to-Treatment | Bacteremia - drug therapy | Klebsiella - enzymology | Gram-Negative Bacterial Infections - drug therapy | Pseudomonas Infections - diagnosis | Survival Rate | Pseudomonas Infections - microbiology | Klebsiella Infections - diagnosis | Gram-Negative Bacterial Infections - diagnosis | Hospital Costs | Escherichia coli Infections - mortality | Pseudomonas aeruginosa - isolation & purification | beta-Lactam Resistance | Acinetobacter Infections - mortality | Klebsiella - isolation & purification | Bacteremia - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Drug Resistance, Multiple, Bacterial | Acinetobacter baumannii - isolation & purification | Adult | Female | beta-Lactamases - metabolism | Acinetobacter Infections - microbiology | Length of Stay | Escherichia coli Infections - diagnosis | Intensive Care Units | Klebsiella Infections - drug therapy | Acinetobacter Infections - diagnosis | Hospital Mortality | Pseudomonas Infections - drug therapy | Acinetobacter Infections - drug therapy | Escherichia coli Infections - microbiology | Treatment Outcome | Bacteremia - diagnosis | Klebsiella Infections - microbiology | Escherichia coli - isolation & purification | Klebsiella Infections - mortality | Aged | Gram-Negative Bacterial Infections - mortality | Drug resistance in microorganisms | Care and treatment | Mass spectrometry | Patient outcomes
Journal Article
2004, Encyclopedia of visual medicine series, ISBN 6610099324, 161
eBook
Infection Control and Hospital Epidemiology, ISSN 0899-823X, 09/2013, Volume 34, Issue 9, pp. 940 - 946
Objective. Urinary tract infections (UTIs) are common among hospitalized patients. Selection of an appropriate antibiotic for this infection requires knowledge...
Hospitalization rates | Pathogens | Databases | Original Article | Escherichia coli | Urinary tract infections | Hospitalization | Infections | Carbapenems | Klebsiella pneumoniae | Enterobacteriaceae | MORTALITY | INFECTIOUS DISEASES | SINGLE-CENTER EXPERIENCE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ORAL-THERAPY | PYELONEPHRITIS | INTENSIVE-CARE-UNIT | ANTIMICROBIAL THERAPY | ANTIBIOTIC-TREATMENT | PNEUMONIA | NOSOCOMIAL INFECTIONS | PATHOGENS | Escherichia coli Infections - drug therapy | United States - epidemiology | Klebsiella Infections - drug therapy | Pseudomonas Infections - drug therapy | Humans | Drug Resistance, Bacterial | Escherichia coli Infections - microbiology | Hospitalization - statistics & numerical data | Gram-Negative Bacterial Infections - drug therapy | Klebsiella Infections - microbiology | Pseudomonas Infections - microbiology | Cross Infection - drug therapy | Urinary Tract Infections - drug therapy | Gram-Negative Bacterial Infections - microbiology | Escherichia coli Infections - epidemiology | Urinary Tract Infections - epidemiology | Klebsiella Infections - epidemiology | Pseudomonas Infections - epidemiology | Cross Infection - microbiology | Drug Resistance, Multiple, Bacterial | Gram-Negative Bacterial Infections - epidemiology | Urinary Tract Infections - microbiology | Cross Infection - epidemiology
Hospitalization rates | Pathogens | Databases | Original Article | Escherichia coli | Urinary tract infections | Hospitalization | Infections | Carbapenems | Klebsiella pneumoniae | Enterobacteriaceae | MORTALITY | INFECTIOUS DISEASES | SINGLE-CENTER EXPERIENCE | PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH | ORAL-THERAPY | PYELONEPHRITIS | INTENSIVE-CARE-UNIT | ANTIMICROBIAL THERAPY | ANTIBIOTIC-TREATMENT | PNEUMONIA | NOSOCOMIAL INFECTIONS | PATHOGENS | Escherichia coli Infections - drug therapy | United States - epidemiology | Klebsiella Infections - drug therapy | Pseudomonas Infections - drug therapy | Humans | Drug Resistance, Bacterial | Escherichia coli Infections - microbiology | Hospitalization - statistics & numerical data | Gram-Negative Bacterial Infections - drug therapy | Klebsiella Infections - microbiology | Pseudomonas Infections - microbiology | Cross Infection - drug therapy | Urinary Tract Infections - drug therapy | Gram-Negative Bacterial Infections - microbiology | Escherichia coli Infections - epidemiology | Urinary Tract Infections - epidemiology | Klebsiella Infections - epidemiology | Pseudomonas Infections - epidemiology | Cross Infection - microbiology | Drug Resistance, Multiple, Bacterial | Gram-Negative Bacterial Infections - epidemiology | Urinary Tract Infections - microbiology | Cross Infection - epidemiology
Journal Article
2009, ISBN 9780807833100, xii, 384 p., [12] p. of plates
Book
Clinical Infectious Diseases, ISSN 1058-4838, 09/2015, Volume 61, Issue suppl 2, pp. S69 - S78
Skin and soft-tissue infections (SSTIs) are an important cause of morbidity and mortality among hospitalized patients and a major therapeutic challenge for...
telavancin | necrotizing infections | skin infections | cellulitis | soft-tissue infections | UNITED-STATES | INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | RISK-FACTORS | NECROTIZING FASCIITIS | CARE-ASSOCIATED INFECTIONS | MICROBIOLOGY | IMMUNOLOGY | COMPLICATED SKIN | STREPTOCOCCAL INFECTIONS | STAPHYLOCOCCUS-AUREUS INFECTIONS | SURGICAL SITE INFECTION | EPIDEMIOLOGY | Skin Diseases, Bacterial - microbiology | Humans | Skin Diseases, Bacterial - drug therapy | Oxazolidinones - therapeutic use | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Skin Diseases, Bacterial - epidemiology | Gram-Positive Bacterial Infections - microbiology | Soft Tissue Infections - drug therapy | Staphylococcal Infections - microbiology | Daptomycin - therapeutic use | Staphylococcal Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Gram-Negative Bacterial Infections - drug therapy | Clinical Trials as Topic | Soft Tissue Infections - epidemiology | Gram-Positive Bacterial Infections - epidemiology | Daptomycin - pharmacology | Soft Tissue Infections - microbiology | Staphylococcal Infections - epidemiology | Oxazolidinones - pharmacology | Gram-Negative Bacterial Infections - epidemiology | Anti-Bacterial Agents - pharmacology | North America - epidemiology | Aminoglycosides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Aminoglycosides - therapeutic use
telavancin | necrotizing infections | skin infections | cellulitis | soft-tissue infections | UNITED-STATES | INFECTIOUS DISEASES | HOSPITALIZED-PATIENTS | RISK-FACTORS | NECROTIZING FASCIITIS | CARE-ASSOCIATED INFECTIONS | MICROBIOLOGY | IMMUNOLOGY | COMPLICATED SKIN | STREPTOCOCCAL INFECTIONS | STAPHYLOCOCCUS-AUREUS INFECTIONS | SURGICAL SITE INFECTION | EPIDEMIOLOGY | Skin Diseases, Bacterial - microbiology | Humans | Skin Diseases, Bacterial - drug therapy | Oxazolidinones - therapeutic use | Gram-Negative Bacterial Infections - microbiology | Microbial Sensitivity Tests | Anti-Bacterial Agents - therapeutic use | Skin Diseases, Bacterial - epidemiology | Gram-Positive Bacterial Infections - microbiology | Soft Tissue Infections - drug therapy | Staphylococcal Infections - microbiology | Daptomycin - therapeutic use | Staphylococcal Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Gram-Negative Bacterial Infections - drug therapy | Clinical Trials as Topic | Soft Tissue Infections - epidemiology | Gram-Positive Bacterial Infections - epidemiology | Daptomycin - pharmacology | Soft Tissue Infections - microbiology | Staphylococcal Infections - epidemiology | Oxazolidinones - pharmacology | Gram-Negative Bacterial Infections - epidemiology | Anti-Bacterial Agents - pharmacology | North America - epidemiology | Aminoglycosides - pharmacology | Gram-Positive Bacterial Infections - drug therapy | Aminoglycosides - therapeutic use
Journal Article
2001, ISBN 1555812139, xvi, 608
This new volume offers a comprehensive survey of Helicobacter biology, ranging from fundamental bacteriology through energy metabolism and synthetic pathways,...
Helicobacter pylori | Helicobacter pylori infections
Helicobacter pylori | Helicobacter pylori infections
Book
2010, ISBN 8763507706, 537
Book
American Journal of Emergency Medicine, ISSN 0735-6757, 2016, Volume 35, Issue 4, pp. 579 - 583
Abstract Objective The aim of this study was to evaluate procalcitonin (PCT) diagnostic accuracy in discriminating gram-negative (GN) from gram-positive (GP)...
Emergency | Positive blood culture | Procalcitonin | Bacterial species | Gram-positive bacteria | Sepsis | Gram-negative bacteria | Infection sites | DIAGNOSIS | MANAGEMENT | ANTIBIOTIC USE | GUIDELINES | MARKERS | CALCITONIN | EMERGENCY MEDICINE | SEPTIC SHOCK | SERUM PROCALCITONIN | RESPIRATORY-TRACT INFECTIONS | Enterococcus faecalis | Escherichia coli | Humans | Middle Aged | Escherichia coli Infections - blood | Male | Acinetobacter Infections - blood | Bacteremia - microbiology | Gram-Negative Bacterial Infections - microbiology | Endocarditis, Bacterial - blood | Staphylococcus haemolyticus | Burkholderia cepacia | Gram-Positive Bacterial Infections - microbiology | Aged, 80 and over | Bacteremia - blood | Endocarditis, Bacterial - microbiology | Female | Urinary Tract Infections - microbiology | Retrospective Studies | Staphylococcal Infections - microbiology | Klebsiella Infections - blood | Burkholderia Infections - microbiology | Staphylococcal Infections - blood | Staphylococcus aureus | Acinetobacter Infections - microbiology | Pneumonia, Bacterial - blood | Calcitonin - blood | Emergency Service, Hospital | Intensive Care Units | Pneumonia, Bacterial - microbiology | Escherichia coli Infections - microbiology | Biomarkers - blood | Klebsiella Infections - microbiology | Gram-Positive Bacterial Infections - blood | Enterococcus faecium | Staphylococcus hominis | Acinetobacter baumannii | Urinary Tract Infections - blood | Staphylococcus epidermidis | Catheter-Related Infections - blood | Catheter-Related Infections - microbiology | Gram-Negative Bacterial Infections - blood | Aged | Burkholderia Infections - blood | Klebsiella pneumoniae | Bacteria | Health aspects | Medical research | Medical examination | Microbiology | Emergency medicine | Analysis | Endocarditis | Medicine, Experimental | Urinary tract infections | Blood | Klebsiella | Multiple sclerosis | Intensive care | Pneumonia | Disease | Laboratories | Lung cancer | Infections | Arthritis | Family medical history | Urinary tract | Microorganisms | Burkholderia | Lupus | Pathogens | Bacterial infections | Medical instruments | Patients | Thyroid cancer | Biomarkers | Cutoffs | Diagnostic systems
Emergency | Positive blood culture | Procalcitonin | Bacterial species | Gram-positive bacteria | Sepsis | Gram-negative bacteria | Infection sites | DIAGNOSIS | MANAGEMENT | ANTIBIOTIC USE | GUIDELINES | MARKERS | CALCITONIN | EMERGENCY MEDICINE | SEPTIC SHOCK | SERUM PROCALCITONIN | RESPIRATORY-TRACT INFECTIONS | Enterococcus faecalis | Escherichia coli | Humans | Middle Aged | Escherichia coli Infections - blood | Male | Acinetobacter Infections - blood | Bacteremia - microbiology | Gram-Negative Bacterial Infections - microbiology | Endocarditis, Bacterial - blood | Staphylococcus haemolyticus | Burkholderia cepacia | Gram-Positive Bacterial Infections - microbiology | Aged, 80 and over | Bacteremia - blood | Endocarditis, Bacterial - microbiology | Female | Urinary Tract Infections - microbiology | Retrospective Studies | Staphylococcal Infections - microbiology | Klebsiella Infections - blood | Burkholderia Infections - microbiology | Staphylococcal Infections - blood | Staphylococcus aureus | Acinetobacter Infections - microbiology | Pneumonia, Bacterial - blood | Calcitonin - blood | Emergency Service, Hospital | Intensive Care Units | Pneumonia, Bacterial - microbiology | Escherichia coli Infections - microbiology | Biomarkers - blood | Klebsiella Infections - microbiology | Gram-Positive Bacterial Infections - blood | Enterococcus faecium | Staphylococcus hominis | Acinetobacter baumannii | Urinary Tract Infections - blood | Staphylococcus epidermidis | Catheter-Related Infections - blood | Catheter-Related Infections - microbiology | Gram-Negative Bacterial Infections - blood | Aged | Burkholderia Infections - blood | Klebsiella pneumoniae | Bacteria | Health aspects | Medical research | Medical examination | Microbiology | Emergency medicine | Analysis | Endocarditis | Medicine, Experimental | Urinary tract infections | Blood | Klebsiella | Multiple sclerosis | Intensive care | Pneumonia | Disease | Laboratories | Lung cancer | Infections | Arthritis | Family medical history | Urinary tract | Microorganisms | Burkholderia | Lupus | Pathogens | Bacterial infections | Medical instruments | Patients | Thyroid cancer | Biomarkers | Cutoffs | Diagnostic systems
Journal Article
2006, The Greenwood Press "Daily life through history" series, ISBN 0313332975, xii, 326
Book
JAMA Surgery, ISSN 2168-6254, 03/2017, Volume 152, Issue 3, pp. 224 - 232
IMPORTANCE: Eravacycline is a novel, fully synthetic fluorocycline antibiotic of the tetracycline class with in vitro activity against clinically important...
SURGERY | FLUOROCYCLINE | MANAGEMENT | PHASE-III | DOUBLE-BLIND | ANTIBIOTIC-RESISTANCE | PLUS METRONIDAZOLE | MECHANISMS | CARBAPENEM-RESISTANT | KLEBSIELLA-PNEUMONIAE | EPIDEMIOLOGY | Appendicitis - complications | Humans | Middle Aged | Abdominal Abscess - drug therapy | Male | Young Adult | Anti-Bacterial Agents - therapeutic use | Bacterial Infections - complications | Peritonitis - microbiology | Aged, 80 and over | Adult | Female | Anti-Bacterial Agents - adverse effects | Double-Blind Method | Bacterial Infections - drug therapy | Gram-Negative Bacteria | Abdominal Abscess - surgery | Treatment Outcome | Abdominal Abscess - microbiology | Intention to Treat Analysis | beta-Lactams - adverse effects | Aged | Tetracyclines - adverse effects | Peritonitis - drug therapy | beta-Lactams - therapeutic use | Tetracyclines - therapeutic use
SURGERY | FLUOROCYCLINE | MANAGEMENT | PHASE-III | DOUBLE-BLIND | ANTIBIOTIC-RESISTANCE | PLUS METRONIDAZOLE | MECHANISMS | CARBAPENEM-RESISTANT | KLEBSIELLA-PNEUMONIAE | EPIDEMIOLOGY | Appendicitis - complications | Humans | Middle Aged | Abdominal Abscess - drug therapy | Male | Young Adult | Anti-Bacterial Agents - therapeutic use | Bacterial Infections - complications | Peritonitis - microbiology | Aged, 80 and over | Adult | Female | Anti-Bacterial Agents - adverse effects | Double-Blind Method | Bacterial Infections - drug therapy | Gram-Negative Bacteria | Abdominal Abscess - surgery | Treatment Outcome | Abdominal Abscess - microbiology | Intention to Treat Analysis | beta-Lactams - adverse effects | Aged | Tetracyclines - adverse effects | Peritonitis - drug therapy | beta-Lactams - therapeutic use | Tetracyclines - therapeutic use
Journal Article
Expert Opinion on Pharmacotherapy, ISSN 1465-6566, 02/2015, Volume 16, Issue 2, pp. 159 - 177
Introduction: Antimicrobial resistance is a well-recognized global threat; thus, the development of strong infection control policies coupled with...
multidrug resistance | antimicrobials | Gram-negative | Gram-positive | Antimicrobials | Multidrug resistance | URINARY-TRACT-INFECTION | GRAM-NEGATIVE ORGANISMS | REDUCED VANCOMYCIN SUSCEPTIBILITY | STAPHYLOCOCCUS-AUREUS BACTEREMIA | LENGTH-OF-STAY | ACINETOBACTER-BAUMANNII INFECTION | METALLO-BETA-LACTAMASE | INTENSIVE-CARE-UNIT | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | PHARMACOLOGY & PHARMACY | BLOOD-STREAM INFECTIONS | Anti-Bacterial Agents - economics | Gram-Positive Bacterial Infections - economics | Cross Infection - economics | Bacterial Infections - economics | Bacterial Infections - drug therapy | Community-Acquired Infections - economics | Humans | Drug Resistance, Bacterial | Gram-Negative Bacterial Infections - drug therapy | Cross Infection - drug therapy | Gram-Negative Bacterial Infections - economics | Gram-Negative Bacterial Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Cross Infection - microbiology | Gram-Positive Bacterial Infections - microbiology | Gram-Positive Bacterial Infections - drug therapy | Community-Acquired Infections - microbiology | Bacterial Infections - microbiology
multidrug resistance | antimicrobials | Gram-negative | Gram-positive | Antimicrobials | Multidrug resistance | URINARY-TRACT-INFECTION | GRAM-NEGATIVE ORGANISMS | REDUCED VANCOMYCIN SUSCEPTIBILITY | STAPHYLOCOCCUS-AUREUS BACTEREMIA | LENGTH-OF-STAY | ACINETOBACTER-BAUMANNII INFECTION | METALLO-BETA-LACTAMASE | INTENSIVE-CARE-UNIT | LACTAMASE-PRODUCING ENTEROBACTERIACEAE | PHARMACOLOGY & PHARMACY | BLOOD-STREAM INFECTIONS | Anti-Bacterial Agents - economics | Gram-Positive Bacterial Infections - economics | Cross Infection - economics | Bacterial Infections - economics | Bacterial Infections - drug therapy | Community-Acquired Infections - economics | Humans | Drug Resistance, Bacterial | Gram-Negative Bacterial Infections - drug therapy | Cross Infection - drug therapy | Gram-Negative Bacterial Infections - economics | Gram-Negative Bacterial Infections - microbiology | Anti-Bacterial Agents - therapeutic use | Community-Acquired Infections - drug therapy | Cross Infection - microbiology | Gram-Positive Bacterial Infections - microbiology | Gram-Positive Bacterial Infections - drug therapy | Community-Acquired Infections - microbiology | Bacterial Infections - microbiology
Journal Article
PLoS ONE, ISSN 1932-6203, 05/2012, Volume 7, Issue 5, p. e37281
Formation of resilient biofilms on medical devices colonized by pathogenic microorganisms is a major cause of health-care associated infection. While in vitro...
ANTIBIOTIC-LOCK TECHNIQUE | CONTROLLED-TRIAL | DIAGNOSIS | THERAPY | BACTEREMIA | IN-VIVO | BIOLOGY | ACCESS SYSTEM | MICE | CANCER | BLOOD-STREAM INFECTIONS | Staphylococcal Infections - drug therapy | Cefazolin - therapeutic use | Gentamicins - therapeutic use | Biofilms - growth & development | Pseudomonas Infections - complications | Rats | Male | Equipment Contamination | Staphylococcal Infections - complications | Anti-Bacterial Agents - therapeutic use | Animals | Staphylococcus epidermidis | Immunosuppression - adverse effects | Catheters, Indwelling - adverse effects | Models, Animal | Pseudomonas aeruginosa | Catheterization, Central Venous - adverse effects | Escherichia coli Infections - complications | Medical research | Medical equipment | Bacterial infections | Escherichia coli | Staphylococcus aureus infections | Medicine, Experimental | Cross infection | Nosocomial infections | Health aspects | Physiological apparatus | Staphylococcus aureus | Pediatrics | Surgical implants | Bioluminescence | Medical innovations | Disseminated infection | Clinical trials | Infections | Microorganisms | E coli | Bacteria | Pathogens | Medical devices | Stability | Complications | Medical instruments | Staphylococcus infections | Disease control | Contamination | Catheters | Biofilms | Antibiotics | Colonization | Cefazolin/therapeutic use | Escherichia coli infections | Biofilms/growth & development | Central Venous/adverse effects | Life Sciences | Staphylococcal Infections/complications/drug therapy | Pseudomonas Infections/complications | Bloodstream infections | Immunosuppression/adverse effects | Bacterial biofilms | Gentamicins/therapeutic use | Catheterization | Indwelling/adverse effects | Escherichia coli Infections/complications | bacterial pathogens | Bacteriology | Microbiology and Parasitology | Animal | Models | Anti-Bacterial Agents/therapeutic use
ANTIBIOTIC-LOCK TECHNIQUE | CONTROLLED-TRIAL | DIAGNOSIS | THERAPY | BACTEREMIA | IN-VIVO | BIOLOGY | ACCESS SYSTEM | MICE | CANCER | BLOOD-STREAM INFECTIONS | Staphylococcal Infections - drug therapy | Cefazolin - therapeutic use | Gentamicins - therapeutic use | Biofilms - growth & development | Pseudomonas Infections - complications | Rats | Male | Equipment Contamination | Staphylococcal Infections - complications | Anti-Bacterial Agents - therapeutic use | Animals | Staphylococcus epidermidis | Immunosuppression - adverse effects | Catheters, Indwelling - adverse effects | Models, Animal | Pseudomonas aeruginosa | Catheterization, Central Venous - adverse effects | Escherichia coli Infections - complications | Medical research | Medical equipment | Bacterial infections | Escherichia coli | Staphylococcus aureus infections | Medicine, Experimental | Cross infection | Nosocomial infections | Health aspects | Physiological apparatus | Staphylococcus aureus | Pediatrics | Surgical implants | Bioluminescence | Medical innovations | Disseminated infection | Clinical trials | Infections | Microorganisms | E coli | Bacteria | Pathogens | Medical devices | Stability | Complications | Medical instruments | Staphylococcus infections | Disease control | Contamination | Catheters | Biofilms | Antibiotics | Colonization | Cefazolin/therapeutic use | Escherichia coli infections | Biofilms/growth & development | Central Venous/adverse effects | Life Sciences | Staphylococcal Infections/complications/drug therapy | Pseudomonas Infections/complications | Bloodstream infections | Immunosuppression/adverse effects | Bacterial biofilms | Gentamicins/therapeutic use | Catheterization | Indwelling/adverse effects | Escherichia coli Infections/complications | bacterial pathogens | Bacteriology | Microbiology and Parasitology | Animal | Models | Anti-Bacterial Agents/therapeutic use
Journal Article
Hepatology, ISSN 0270-9139, 05/2012, Volume 55, Issue 5, pp. 1551 - 1561
Epidemiology, risk factors, and clinical effect of infections by multiresistant bacteria in cirrhosis are poorly known. This work was a prospective evaluation...
PERITONITIS | LIVER-CIRRHOSIS | ACQUIRED INFECTIONS | ESCHERICHIA-COLI | ACQUISITION | RESISTANCE | HEPATORENAL-SYNDROME | SEPSIS | NORFLOXACIN PROPHYLAXIS | GASTROENTEROLOGY & HEPATOLOGY | KLEBSIELLA-PNEUMONIAE | Multivariate Analysis | Prevalence | Prognosis | Community-Acquired Infections - epidemiology | Gram-Positive Bacteria - drug effects | Humans | Middle Aged | Male | Enterobacteriaceae - isolation & purification | Gram-Negative Bacteria - isolation & purification | Liver Cirrhosis - epidemiology | Microbial Sensitivity Tests | Community-Acquired Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Statistics, Nonparametric | Female | Retrospective Studies | beta-Lactamases - metabolism | Bacterial Infections - microbiology | Cross Infection - epidemiology | Liver Cirrhosis - diagnosis | Bacterial Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Risk Factors | Proportional Hazards Models | Cross Infection - drug therapy | Gram-Negative Bacteria - drug effects | Spain - epidemiology | Cross Infection - microbiology | Bacterial Infections - epidemiology | Enterobacteriaceae - drug effects | Survival Analysis | Gram-Positive Bacteria - isolation & purification | Liver Cirrhosis - microbiology | Aged | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Community-Acquired Infections - microbiology | Cohort Studies | Bacterial infections | Antibiotics | Mortality | Bacteria | Staphylococcus infections | Nosocomial infections | Epidemiology
PERITONITIS | LIVER-CIRRHOSIS | ACQUIRED INFECTIONS | ESCHERICHIA-COLI | ACQUISITION | RESISTANCE | HEPATORENAL-SYNDROME | SEPSIS | NORFLOXACIN PROPHYLAXIS | GASTROENTEROLOGY & HEPATOLOGY | KLEBSIELLA-PNEUMONIAE | Multivariate Analysis | Prevalence | Prognosis | Community-Acquired Infections - epidemiology | Gram-Positive Bacteria - drug effects | Humans | Middle Aged | Male | Enterobacteriaceae - isolation & purification | Gram-Negative Bacteria - isolation & purification | Liver Cirrhosis - epidemiology | Microbial Sensitivity Tests | Community-Acquired Infections - drug therapy | Drug Resistance, Multiple, Bacterial | Statistics, Nonparametric | Female | Retrospective Studies | beta-Lactamases - metabolism | Bacterial Infections - microbiology | Cross Infection - epidemiology | Liver Cirrhosis - diagnosis | Bacterial Infections - drug therapy | Methicillin-Resistant Staphylococcus aureus - drug effects | Risk Factors | Proportional Hazards Models | Cross Infection - drug therapy | Gram-Negative Bacteria - drug effects | Spain - epidemiology | Cross Infection - microbiology | Bacterial Infections - epidemiology | Enterobacteriaceae - drug effects | Survival Analysis | Gram-Positive Bacteria - isolation & purification | Liver Cirrhosis - microbiology | Aged | Methicillin-Resistant Staphylococcus aureus - isolation & purification | Community-Acquired Infections - microbiology | Cohort Studies | Bacterial infections | Antibiotics | Mortality | Bacteria | Staphylococcus infections | Nosocomial infections | Epidemiology
Journal Article
1998, ISBN 9780851155340, xiii, 221
Book